Irland - engelska - HPRA (Health Products Regulatory Authority)

fujisawa deutschland gmbh - theophylline -

Irland - engelska - HPRA (Health Products Regulatory Authority)

fujisawa deutschland gmbh - theophylline -

Irland - engelska - HPRA (Health Products Regulatory Authority)

fujisawa deutschland gmbh - theophylline -

Irland - engelska - HPRA (Health Products Regulatory Authority)

fujisawa deutschland gmbh - theophylline -

Irland - engelska - HPRA (Health Products Regulatory Authority)

fujisawa deutschland gmbh - theophylline - capsules modified release - 500 milligram

USA - engelska - NLM (National Library of Medicine)

fujisawa healthcare, inc. - ceftizoxime sodium (unii: 26337d5x88) (ceftizoxime - unii:c43c467dpe) - injection, powder, lyophilized, for solution - 1 g - cefizox (ceftizoxime for injection, usp) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. lower respiratory tract infections caused by klebsiella spp.; proteus mirabilis ; escherichia coli; haemophilus influenzae including ampicillin‐resistant strains; staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); serratia spp.; enterobacter spp.; bacteroides spp.; and streptococcus spp. including s. pneumoniae , but excluding enterococci. urinary tract infections caused by staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); escherichia coli ; pseudomonas spp. including p. aeruginosa ; proteus mirabilis ; p. vulgaris ; providencia rettgeri (formerly proteus rettgeri ) and morganella morganii (formerly proteus morganii ); klebsiella spp.; serratia spp. including s. marcescens ; and enterobacter spp. gonorrhea including uncomplicated cervical and urethral gonorrhea caused by neisseria gonorrhoeae . pelvic inflamma

USA - engelska - NLM (National Library of Medicine)

fujisawa healthcare, inc. - ceftizoxime sodium (unii: 26337d5x88) (ceftizoxime - unii:c43c467dpe) - injection, powder, lyophilized, for solution - 500 mg - cefizox (ceftizoxime for injection, usp) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. lower respiratory tract infections caused by klebsiella spp.; proteus mirabilis ; escherichia coli; haemophilus influenzae including ampicillin­resistant strains; staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); serratia spp.; enterobacter spp.; bacteroides spp.; and streptococcus spp. including s. pneumoniae , but excluding enterococci. urinary tract infections caused by staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); escherichia coli ; pseudomonas spp. including p. aeruginosa ; proteus mirabilis ; p. vulgaris ; providencia rettgeri (formerly proteus rettgeri ) and morganella morganii (formerly proteus morganii ); klebsiella spp.; serratia spp. including s. marcescens ; and enterobacter spp. gonorrhea including uncomplicated cervical and urethral gonorrhea caused by neisseria gonorrhoeae . pelvic inflamma

Kanada - engelska - Health Canada

fujisawa pharmaceutical co, division of fujisawa canada inc. - adenosine - liquid - 3mg - adenosine 3mg - miscellaneous cardiac drugs

Kanada - engelska - Health Canada

fujisawa pharmaceutical co, division of fujisawa canada inc. - adenosine - liquid - 3mg - adenosine 3mg - miscellaneous cardiac drugs

Egypten - engelska - EDA (Egyptian Drug Authority)

hikma -jordan in corporation with fujisawa- japan - capsule